Welcome to our dedicated page for Neuropace news (Ticker: NPCE), a resource for investors and traders seeking the latest updates and insights on Neuropace stock.
NeuroPace, Inc. is a leading commercial-stage medical device company based in Silicon Valley, focused on transforming the lives of individuals suffering from epilepsy. Founded with the mission to design, develop, manufacture, and market implantable devices for neurological disorders, NeuroPace has made significant strides in the field of responsive neurostimulation.
At the core of NeuroPace's innovation is the RNS® System. This award-winning technology, akin to a pacemaker for the heart, is the world's first and only medical device capable of monitoring and responding to brain activity in real-time. The RNS® System is specifically designed to treat epilepsy, a neurological disorder that affects approximately 1% of the global population, by reducing or eliminating debilitating seizures. The system is primarily used in hospital facilities, particularly Level 4 Comprehensive Epilepsy Centers (CECs).
Beyond epilepsy, the promise of responsive neurostimulation extends to several other disabling medical conditions, potentially improving the quality of life for millions worldwide. NeuroPace is recognized for its patient-centric approach and continuous advancements in the field of neurological treatments.
Recent achievements include the RNS® System being featured in over 50 scientific presentations and posters, underscoring its impact and the ongoing research dedicated to improving its efficacy. The company also maintains significant partnerships and collaborations to further its mission and ensure the RNS® System remains at the forefront of medical innovation.
Financially, NeuroPace derives nearly all its revenue from the sales of the RNS® System, highlighting the product's centrality to the company’s business model. With a strong focus on patient outcomes and continuous technological advancement, NeuroPace is well-positioned to lead in the field of neurological disorder treatments.
NeuroPace, Inc. (Nasdaq: NPCE) will report its Q3 2022 financial results after market close on November 8, 2022. A conference call will follow at 1:30 PM PT / 4:30 PM ET, allowing investors to listen live or via archived webcast on their website. NeuroPace focuses on enhancing the quality of life for those with epilepsy using its RNS System, a brain-responsive treatment platform aimed at reducing seizures, particularly for drug-resistant epilepsy patients. This innovation may offer a more personalized care approach for various brain disorders.
NeuroPace, Inc. (NASDAQ: NPCE) has announced the initiation of the NAUTILUS clinical study, evaluating the RNS® System for treating drug-resistant idiopathic generalized epilepsy (IGE) in patients aged 12 and older. The first patient was treated at Vanderbilt Health in Nashville, TN. This pivotal study aims to demonstrate the safety and effectiveness of the RNS System, which utilizes brain-responsive neuromodulation. The RNS System, already FDA-approved for focal epilepsy, has received Breakthrough Device Designation for IGE treatment, highlighting its potential to fill a significant unmet medical need.
MOUNTAIN VIEW, Calif., Aug. 23, 2022 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE) announced its participation in the Morgan Stanley 20th Annual Global Healthcare Conference. Management will present on September 13 at 12:20 p.m. Eastern Time. The event will be accessible via a live webcast and archived for at least 90 days on the company’s website.
NeuroPace focuses on transforming the lives of epilepsy patients with its RNS System, the first brain-responsive platform for real-time treatment, aiming to improve outcomes for those with drug-resistant epilepsy.
NeuroPace (Nasdaq: NPCE) reported Q2 2022 revenues of $10.2 million, down from $12.6 million year-over-year. The initial implant revenue was $8.0 million, a decrease from $9.2 million, primarily due to reduced patient volumes in Epilepsy Monitoring Units (EMUs) and COVID-19 cancellations. The net loss widened to $12.7 million from $8.5 million in the previous year. Guidance for 2022 forecasts total revenues between $43 million and $45 million, driven by new partnerships and an expanded sales team.
NeuroPace (Nasdaq: NPCE) has entered a commercialization agreement with DIXI Medical to exclusively market and sell its diagnostic electrodes for epilepsy in the U.S. This agreement takes effect on October 1, 2022. NeuroPace will promote stereoelectroencephalography (SEEG) electrodes, crucial for pinpointing seizure sources in patients with drug-resistant epilepsy. DIXI will support physicians with education and outreach, receiving an upfront payment and subsequent payments in 2023 and 2024. This partnership aims to enhance treatment options for epilepsy patients through combined expertise.
NeuroPace, Inc. (Nasdaq: NPCE) announced it will report its second quarter financial results on August 11, 2022, after market close. The company focuses on improving the lives of individuals with epilepsy through its innovative RNS System, the first of its kind designed to provide real-time treatment at the seizure source. A conference call will follow at 1:30 PM PT, with a link available for investors to listen. Archived recordings will be accessible on the company’s website for at least 90 days.
MOUNTAIN VIEW, Calif., May 13, 2022 – NeuroPace, a medical device company focused on epilepsy treatment, will present at the 2022 RBC Capital Markets Global Healthcare Conference. CEO Mike Favet’s presentation is set for May 17 at 9:30 a.m. ET. A live webcast and archived recording will be accessible on the company’s website for 90 days. NeuroPace’s innovative RNS System offers personalized, real-time treatment for drug-resistant epilepsy, aiming to enhance care standards and improve outcomes for patients with various brain disorders.
NeuroPace, a medical device company focused on epilepsy, reported Q1 2022 revenue of $11.4 million, up from $11.2 million in Q1 2021. Initial implant revenue rose to $8.8 million, a significant increase from $8.1 million the previous year. However, replacement implant revenue dropped to $2.6 million from $3.1 million. The company experienced a net loss of $11.5 million, wider than the $8.8 million loss in Q1 2021. For 2022, they project revenue between $45 million and $48 million and a gross margin in the mid-70% range.
NeuroPace, Inc. has commenced the RESPONSE clinical trial, the first study assessing the efficacy of the RNS System for treating drug-resistant focal epilepsy in adolescents aged 12 to 17. Conducted at Westchester Medical Center, this pivotal study aims to confirm the system's safety and effectiveness as an adjunctive therapy. The RNS System is uniquely designed to deliver real-time treatment based on individual brain patterns, offering hope to over 1 million adolescents with epilepsy who are resistant to standard medication.
NeuroPace, Inc. (Nasdaq: NPCE) will release its financial results for Q1 2022 on May 12, 2022, after market close. A conference call will follow at 1:30 p.m. PT / 4:30 p.m. ET, accessible via phone or webcast on their website. NeuroPace specializes in medical devices for epilepsy treatment, with its RNS System being the first brain-responsive platform delivering timely, personalized therapies. This innovative approach aims to improve care for drug-resistant epilepsy patients and potentially others with brain disorders, enhancing treatment outcomes.
FAQ
What is the current stock price of Neuropace (NPCE)?
What is the market cap of Neuropace (NPCE)?
What is NeuroPace, Inc. known for?
What medical condition does the RNS® System primarily target?
Where is NeuroPace, Inc. based?
How does the RNS® System work?
Who are the primary customers for the RNS® System?
What recent achievements has NeuroPace made?
How does NeuroPace generate revenue?
Can the RNS® System treat conditions other than epilepsy?
What makes the RNS® System unique?
Who can be contacted for investor-related inquiries at NeuroPace?
